Phaseline

Targets › DYSTROPHIN

DYSTROPHIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jan 2027.

Open in Phaseline: the race on DYSTROPHIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Daiichi SankyoDS-5141b (Renadirsen)
Antisense oligonucleotide targeting dystrophin pre-mRNA
DYSTROPHINPhase 2Duchenne Muscular DystrophyJan 2027

Conditions

Duchenne Muscular Dystrophy (1)

Modalities

other (1)

Companies

Daiichi Sankyo (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.